“Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients As Young As 2 Years”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s766, https://doi.org/10.25251/94s3pn30.